Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Current Liabilities to Total Liabilities Ratio 3 year CAGR for the quarter ending March 31, 2024: 126.28%

Biomea Fusion Inc Current Liabilities to Total Liabilities Ratio 3 year CAGR is 126.28% for the quarter ending March 31, 2024. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Biomea Fusion Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2023 was 0.64, a -19.30% change year over year.
  • Biomea Fusion Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2022 was 0.79, a 1,100.07% change year over year.
  • Biomea Fusion Inc Current Liabilities to Total Liabilities Ratio for the quarter ending March 31, 2021 was 0.07.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email